Treatment with irinotecan (cpt-11) and an egfr-inhibitor

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/4745 (2006.01) A61K 31/4706 (2006.01) A61K 31/517 (2006.01) A61K 31/519 (2006.01) A61K 31/5377 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2566971

The present invention provides a method for manufacturing a medicament for treating tumors or tumor metastases, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and irinotecan is used, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and irinotecan combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practising this invention is the compound erlotinib HCl (also known as TarcevaTM).

Cette invention concerne une méthode destinée à la conception d'un médicament pour le traitement de tumeurs ou de métastases tumorales. Ladite méthode est caractérisée en ce qu'une quantité efficace thérapeutiquement d'un inhibiteur de la kinase EGFR et d'irinotecan est utilisée, avec ou sans agents supplémentaires ou traitements, tels que d'autres médicaments anticancéreux ou une radiothérapie. Cette invention a aussi pour objet une composition pharmaceutique qui contient un mélange d'inhibiteur de la kinase EGFR et d'irinotecan en combinaison avec un excipient acceptable pharmaceutiquement. Un exemple préféré d'un inhibiteur de la kinase EGFR pouvant être utilisé dans la mise en pratique de cette méthode est le composé d'erlotinibe HCl (également connu sous le nom de Tarceva<SP>TM</SP>).

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Treatment with irinotecan (cpt-11) and an egfr-inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment with irinotecan (cpt-11) and an egfr-inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment with irinotecan (cpt-11) and an egfr-inhibitor will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1380480

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.